Cheng Hui-Fang, Harris Raymond C
Division of Nephrology, S 3223 MCN, Vanderbilt University School of Medicine, Nashville, TN 37232-2372, USA.
Curr Hypertens Rep. 2003 Feb;5(1):87-92. doi: 10.1007/s11906-003-0016-y.
With the development and clinical implementation of the new cyclooxygenase (COX)-2 inhibitors, their safety, including the effects on renal function and blood pressure, is attracting increasing attention. In the kidney, COX-2 is constitutively expressed and is highly regulated in response to alterations in intravascular volume. COX-2 metabolites have been implicated in mediation of renin release, regulation of sodium excretion, and maintenance of renal blood flow. Similar to conventional nonsteroidal anti-inflammatory drugs, inhibition of COX-2 may cause modest elevations in blood pressure in a minority of subjects. COX-2 inhibitors may also exacerbate pre-existing hypertension or interfere with other antihypertensive drugs. Special caution should be taken in patients with volume depletion or decreased organ perfusion.
随着新型环氧化酶(COX)-2抑制剂的研发及其在临床上的应用,其安全性,包括对肾功能和血压的影响,正受到越来越多的关注。在肾脏中,COX-2呈组成性表达,并在血管内容量改变时受到高度调节。COX-2代谢产物参与肾素释放的介导、钠排泄的调节以及肾血流量的维持。与传统非甾体抗炎药类似,抑制COX-2可能在少数受试者中导致血压适度升高。COX-2抑制剂也可能使已有的高血压病情加重或干扰其他抗高血压药物。对于血容量减少或器官灌注降低的患者应特别谨慎。